When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

October 13, 2020


Related news

In the news

December 14, 2021

Digital Therapeutics Shaping the Future of Care

Managed Healthcare Executive

In the news

November 22, 2021

A legacy of leadership: Chris Bent

University of Minnesota